artificial intelligence

The firm is engaging with regulators about its recently validated Ataraxis Breast test, which it hopes to make available for clinical use next year.

Hollings researchers will develop AI-driven tools to better match cancer patients to marketed therapies and clinical trials.

The firms will initially develop a tool to identify NSCLC patients with EGFR mutations who can benefit from targeted therapy.